Murtaza Ahmed, M.D. Titles and Appointments Clinical Assistant Professor Schools Medical School Departments Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Murtaza Ahmed, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Hospital Medicine. Dr. Ahmed holds a bachelor's degree in biology from the University of Texas at Dallas, which he earned summa cum laude. He received his medical degree from UT Southwestern and completed internal medicine residency training at Cedars-Sinai Medical Center. Dr. Murtaza Ahmed’s clinical and research interests center on immunotherapy, oncology, and the complex interplay between cancer treatments and immune‑related toxicities. His work explores factors influencing the effectiveness of immune checkpoint inhibitors, including body mass index, dosing strategies, treatment timing, and tumor burden, and examines rare or exceptional clinical responses in difficult‑to‑treat malignancies such as pancreatic adenosquamous carcinoma. He has also contributed to research on autoimmune complications related to cancer therapy, as well as thromboprophylaxis in patients undergoing chemotherapy. Collectively, his publications reflect a strong commitment to advancing precision oncology and improving outcomes for patients receiving immunotherapy. Education Undergraduate University of Texas at Dallas (2017), Biology Medical School (2022) Publications Featured Publications A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy. Ahmed M, Larson BK, Osipov A, Azad N, Hendifar A, Oncotarget 2024 Oct 15 741-747 Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice. von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE, Front Immunol 2024 15 1351739 Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE, J Immunother Cancer 2021 Jun 9 6 Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. Meng X, Ahmed M, Courtney KD, Arafat W, Ibrahim I, Margulis V, Nichols C, Bagrodia A, Front Oncol 2021 11 724682 Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Popat V, Lu R, Ahmed M, Park JY, Xie Y, Gerber DE, Oncologist 2020 Mar GCNA Preserves Genome Integrity and Fertility Across Species. Bhargava V, Goldstein CD, Russell L, Xu L, Ahmed M, Li W, Casey A, Servage K, Kollipara R, Picciarelli Z, Kittler R, Yatsenko A, Carmell M, Orth K, Amatruda JF, Yanowitz JL, Buszczak M, Dev Cell 2020 01 52 1 38-52.e10 Results 1-6 of 6 1
